NAC & Respiratory Health

NAC was first brought to market in 1963 as a mucolytic (Mucomyst) — a drug that thins thick mucus by cleaving the disulfide bonds that cross-link mucin glycoproteins. Sixty years later it remains one of the most studied agents in chronic respiratory disease, with particularly strong evidence in chronic obstructive pulmonary disease (COPD), chronic bronchitis, and bronchiectasis. Its mechanism of action in the lung is a triple play: direct chemical scissors on mucus cross-links, restoration of airway glutathione, and direct free-radical scavenging against the ROS generated by cigarette smoke, infection, and neutrophilic inflammation.

Table of Contents

  1. Mucolytic and Antioxidant Mechanism
  2. COPD: BRONCUS, PANTHEON, HIACE, and the Cochrane Review
  3. Chronic Bronchitis
  4. Cystic Fibrosis
  5. Idiopathic Pulmonary Fibrosis
  6. Bronchiectasis
  7. Influenza and Viral Respiratory Infection
  8. Asthma
  9. Pneumonia and ICU / Ventilator Settings
  10. Dosing
  11. Safety
  12. References
  13. Connections
  14. Featured Videos

Mucolytic and Antioxidant Mechanism

Chemical Scissors on Mucus

Mucus in the airway is dominated by enormous glycoprotein polymers called mucins (principally MUC5AC and MUC5B) cross-linked by disulfide bonds between cysteine residues. Sheffner (1963, Ann NY Acad Sci) first showed that NAC's free thiol attacks these S–S bonds via thiol-disulfide exchange, cleaving them and reducing mucus viscosity by roughly 60–80% within minutes of direct contact. This is the basis of its original respiratory indication.

Glutathione Restoration in Airway Lining Fluid

Airway lining fluid has an unusually high glutathione concentration (~100 micromolar, roughly 100-fold plasma) because neutrophils and alveolar macrophages generate substantial ROS as part of normal host defense. Cigarette smoke, chronic bronchitis, and cystic fibrosis deplete this pool. Bridgeman 1991 (Thorax) showed that oral NAC 600 mg three times daily for 5 days significantly raised bronchoalveolar lavage glutathione — proof that oral dosing reaches the lung in active form.

Direct Free-Radical Scavenging

Independently of glutathione, NAC's free thiol scavenges hydroxyl radicals and hypochlorous acid (generated by neutrophil myeloperoxidase). Oxidative stress also upregulates MUC5AC expression via EGFR signaling — so reducing oxidative stress indirectly reduces mucus production, not just mucus viscosity.

COPD: BRONCUS, PANTHEON, HIACE, and the Cochrane Review

COPD is NAC's most studied modern indication. The question across trials has evolved from "does it improve spirometry?" (answer: no) to "does it reduce exacerbations?" (answer: yes at the right dose). The right dose turns out to be 1,200 mg/day.

BRONCUS Trial (Decramer 2005)

523 patients with moderate-to-severe COPD randomized to NAC 600 mg once daily versus placebo for 3 years. No significant effect on FEV1 decline. Exacerbation rate not significantly reduced overall, but a subgroup analysis did show benefit in patients not taking inhaled corticosteroids (Lancet 365:1552). The takeaway: 600 mg once daily is sub-therapeutic.

PANTHEON Trial (Zheng 2014) — The Positive Dose-Response

Randomized 1,006 Chinese patients with moderate-to-severe COPD to NAC 600 mg twice daily (1,200 mg/day) versus placebo for 1 year. Exacerbation rate fell from 1.49/year (placebo) to 1.16/year (NAC), a 22% risk reduction (RR 0.78, 95% CI 0.67–0.90, p=0.001). Effect was consistent across subgroups including patients already on inhaled corticosteroids. Published in Lancet Respir Med 2(3):187.

HIACE Trial (Tse 2013)

Hong Kong RCT in 120 stable COPD patients, NAC 600 mg BID for 1 year. Reduced exacerbation frequency (0.96 vs 1.71/year) and improved small-airway function (Chest 144:106). Confirmed PANTHEON's signal.

Cochrane Review (Poole 2019)

Pooled 34 trials of over 6,000 chronic bronchitis / COPD patients. Mucolytics reduced the odds of an exacerbation by ~27% (OR 0.73, 95% CI 0.66–0.80). Number needed to treat (NNT) roughly 8 patients to prevent one exacerbation. No consistent effect on FEV1 or mortality. Larger benefit in studies using at least 1,200 mg/day.

Guidelines

GOLD reports acknowledge NAC as a maintenance option for COPD patients not on inhaled corticosteroids who have recurrent exacerbations, citing PANTHEON. The evidence-based COPD dose is 600 mg twice daily.

Chronic Bronchitis

Chronic bronchitis — productive cough at least 3 months a year for 2 consecutive years — was NAC's original European indication from the 1960s-70s.

Stey Meta-Analysis 2000

Pooled 39 RCTs of oral NAC in chronic bronchitis (Eur Respir J 16:253). NAC reduced the odds of experiencing at least one exacerbation per winter (OR 0.52, 95% CI 0.40–0.67) — approximately a 29% relative risk reduction. 61% of NAC patients reported symptomatic improvement versus 35% of placebo (OR 2.9). NNT around 5.8.

Grandjean Meta-Analysis 2000

11 placebo-controlled studies showed a 48.5% reduction in exacerbation days per patient per winter (Clin Ther 22:209).

Dose 400–600 mg twice daily, long-term use. NAC has been a standard European over-the-counter mucolytic (Fluimucil, NAC 600 Hexal) for this indication for decades.

Cystic Fibrosis

CF airways are filled with thick, neutrophil-dominated, DNA-rich sputum. NAC has been studied for both mucolysis and antioxidant support (CF patients have low airway glutathione despite normal plasma levels).

Inhaled NAC

Historically 10% or 20% nebulized NAC was used, but it caused bronchospasm in a substantial minority and offered no advantage over hypertonic saline or dornase alfa (Pulmozyme, rhDNase). Inhaled NAC has largely fallen out of favor in CF care.

Oral High-Dose NAC

NAC is not first-line for CF mucus clearance (rhDNase and hypertonic saline are). High-dose oral NAC may modulate neutrophilic inflammation but does not reliably improve pulmonary function.

Idiopathic Pulmonary Fibrosis

IPF is characterized by progressive fibrosis of the lung parenchyma. Oxidative stress is mechanistically implicated, and NAC was once a cornerstone of "triple therapy" with prednisone and azathioprine.

IFIGENIA 2005 — Suggested Benefit

Demedts randomized 182 IPF patients to NAC 1,800 mg/day added to prednisone + azathioprine versus standard therapy alone for 1 year. NAC arm showed slower decline in vital capacity and DLco (NEJM 353:2229). This drove widespread triple-therapy prescribing.

PANTHER-IPF 2012/2014 — The Definitive Reversal

The IPF Clinical Research Network's PANTHER trial published in two stages:

Oldham's 2015 post-hoc (AJRCCM) suggested TOLLIP genotype may identify IPF patients who benefit from NAC, but this has not been prospectively validated. ATS/ERS guidelines give NAC a conditional recommendation against routine use in IPF. Pirfenidone and nintedanib are the guideline-directed antifibrotics.

Bronchiectasis

BENE Trial (Qi 2019)

161 non-CF bronchiectasis patients randomized to NAC 600 mg twice daily for 12 months vs usual care. Exacerbations dropped from 1.2 to 0.5 per year (p<0.001), a 60% reduction. Improved quality-of-life scores. No change in FEV1 (Respir Res 20:73). Open-label design is a limitation but the effect size is large. British Thoracic Society guidelines mention mucoactive agents as an option in bronchiectasis.

Influenza and Viral Respiratory Infection

De Flora 1997 — The Classic Study

262 older adults with chronic non-respiratory degenerative disease were randomized to NAC 600 mg twice daily versus placebo for 6 months during influenza season (Eur Respir J 10:1535). NAC did not prevent infection — serologic seroconversion rates were similar (75% vs 79%) — but dramatically reduced symptomatic illness: only 25% of NAC-treated infected subjects developed clinical flu versus 79% of placebo. Days with symptoms and days in bed were significantly reduced.

Mechanism: NAC does not block viral entry but appears to blunt the symptomatic immuno-inflammatory response through glutathione replenishment and NF-kB suppression in activated immune cells.

Later Mechanistic Work

Asthma

Evidence is limited and mixed. Oxidative stress is implicated in severe neutrophilic asthma, providing biological rationale, but clinical trials are small.

Critical safety note: inhaled NAC can trigger bronchospasm in asthmatic airways due to direct irritant effect of the acidic thiol solution. When nebulizing NAC in any reactive-airway patient, pre-treat with a short-acting bronchodilator. NAC is not standard asthma therapy.

Pneumonia and ICU / Ventilator Settings

Dosing

Oral (Most Common)

Nebulized

Bioavailability

Oral NAC has 4–10% intact-molecule bioavailability. Most systemic effect comes from the cysteine and glutathione it becomes rather than intact NAC. Inhaled/nebulized administration produces a more rapid, localized airway effect.

Safety

References

  1. Sheffner AL. The reduction in vitro in viscosity of mucoprotein solutions by a new mucolytic agent, N-acetyl-L-cysteine. Ann NY Acad Sci 1963;106:298–310. PMID 13977050.
  2. Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of NAC on outcomes in COPD (BRONCUS). Lancet 2005;365:1552–1560. PMID 15866309.
  3. Zheng JP, Wen FQ, Bai CX, et al. Twice-daily NAC 600 mg for exacerbations of COPD (PANTHEON). Lancet Respir Med 2014;2:187–194. PMID 24621680.
  4. Tse HN, Raiteri L, Wong KY, et al. High-dose NAC in stable COPD (HIACE). Chest 2013;144:106–118. PMID 23348146.
  5. Poole P, Sathananthan K, Fortescue R. Mucolytic agents versus placebo for chronic bronchitis or COPD. Cochrane Database Syst Rev 2019;CD001287. PMID 31107966.
  6. Stey C, Steurer J, Bachmann S, Medici TC, Tramer MR. The effect of oral NAC in chronic bronchitis: a quantitative systematic review. Eur Respir J 2000;16:253–262. PMID 10968500.
  7. Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long-term NAC in chronic bronchopulmonary disease. Clin Ther 2000;22:209–221. PMID 10743980.
  8. Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA. High-dose oral NAC modulates inflammation in cystic fibrosis. PNAS 2006;103:4628–4633. PMID 16537378.
  9. Conrad C, Lymp J, Thompson V, et al. Long-term oral NAC in cystic fibrosis. J Cyst Fibros 2015;14:219–227. PMID 25228446.
  10. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in IPF (IFIGENIA). NEJM 2005;353:2229–2242. PMID 16306520.
  11. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ (IPFCRN). Prednisone, azathioprine, and NAC for pulmonary fibrosis (PANTHER-IPF). NEJM 2012;366:1968–1977. PMID 22607134.
  12. Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G. Randomized trial of acetylcysteine in IPF. NEJM 2014;370:2093–2101. PMID 24836309.
  13. Oldham JM, Ma SF, Martinez FJ, et al. TOLLIP, MUC5B, and the response to NAC in IPF. AJRCCM 2015;192:1475–1482. PMID 26331942.
  14. Qi Q, Ailiyaer Y, Liu R, et al. Effect of NAC on exacerbations of bronchiectasis (BENE). Respir Res 2019;20:73. PMID 30975143.
  15. De Flora S, Grassi C, Carati L. Attenuation of influenza-like symptomatology with NAC. Eur Respir J 1997;10:1535–1541. PMID 9230243.
  16. Geiler J, Michaelis M, Naczk P, et al. NAC inhibits H5N1 influenza A virus replication. Biochem Pharmacol 2010;79:413–420. PMID 19732754.
  17. Cazzola M, Calzetta L, Page C, et al. NAC influence on chronic bronchitis or COPD exacerbations: meta-analysis. Eur Respir Rev 2015;24:451–461. PMID 26324807.
  18. Santus P, Corsico A, Solidoro P, et al. Oxidative stress and respiratory system: pharmacological reappraisal of NAC. COPD 2014;11:705–717. PMID 24787454.
  19. Sadowska AM, Manuel-y-Keenoy B, De Backer WA. Antioxidant and anti-inflammatory efficacy of NAC in COPD. Pulm Pharmacol Ther 2007;20:9–22. PMID 16458553.
  20. Rushworth GF, Megson IL. Existing and potential therapeutic uses for NAC. Pharmacol Ther 2014;141:150–159. PMID 24080471.
  21. Dekhuijzen PN. Antioxidant properties of NAC in COPD. Eur Respir J 2004;23:629–636. PMID 15083766.

Connections

↑ Back to Table of Contents

Video Thumbnail

NAC for COPD and Chronic Bronchitis

Video Thumbnail

Mucolytics and Lung Health

Video Thumbnail

PANTHEON Trial — NAC and COPD Exacerbations